Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study

(2023) Maxim Grymonprez et al.   Frontiers in Pharmacology

Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis

(2022) Maxim Grymonprez et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

(2022) Yunwen Xu et al.   Journal of the American Heart Association

Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: A Belgian nationwide cohort study

(2022) Maxim Grymonprez et al.   Frontiers in Cardiovascular Medicine

Drug–drug interactions with direct oral anticoagulants: development of a consensus list for ambulatory care

(2022) Andreas Capiau et al.   International Journal of Clinical Pharmacy

Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study

(2021) Amichai Perlman et al.   CNS DRUGS

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

(2021) Jan Steffel et al.   EUROPACE

The Impact of Strong Inducers on Direct Oral Anticoagulant Levels

(2021) Anne-Laure Sennesael et al.   AMERICAN JOURNAL OF MEDICINE

Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control Study

(2021) Naomi Gronich et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population‐based nested case–control study

(2020) Yumao Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

(2020) Sarah Hanigan et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants

(2020) Victoria Allan et al.   Journal of Comparative Effectiveness Research

Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function

(2020) Phuong Pham et al.   JAMA Network Open

Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients

(2020) Johan Holm et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis

(2020) Maxim Grymonprez et al.   Frontiers in Pharmacology

Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem

(2018) Jenna W. Bartlett et al.   ANNALS OF PHARMACOTHERAPY

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)

(2018) Sinéad M Langan et al.   BMJ-British Medical Journal

Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation

(2017) Shang-Hung Chang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial

(2014) Benjamin A. Steinberg et al.   HEART RHYTHM

Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management)

(2011) Sanjeev Saksena et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY